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ABSTRACT
Introduction: The PIONEER trial programme
showed that, after 52 weeks, the novel oral glu-
cagon-like peptide-1 (GLP-1) analogue
semaglutide 14 mg was associated with signifi-
cantly greater reductions in glycated hae-
moglobin (HbA1c) versus a sodium-glucose
cotransporter-2 inhibitor (empagliflozin 25 mg),
a dipeptidyl peptidase-4 inhibitor (sitagliptin
100 mg) and an injectable GLP-1 analogue (li-
raglutide 1.8 mg). The aim of the present
analysis was to assess the long-term cost-effec-
tiveness of oral semaglutide 14 mg versus each
of these comparators in the UK setting.
Methods: Analyses were performed from a
healthcare payer perspective using the IQVIA
CORE Diabetes Model, in which outcomes were
projected over patient lifetimes (50 years).
Baseline cohort characteristics and treatment
effects were based on 52-week data from the
PIONEER 2, 3 and 4 randomised controlled tri-
als, comparing oral semaglutide with empagli-
flozin, sitagliptin and liraglutide, respectively.
Treatment switching occurred when HbA1c
exceeded 7.5% (58 mmol/mol). Utilities, treat-
ment costs and costs of diabetes-related com-
plications (in pounds sterling [GBP]) were taken
from published sources. The acquisition cost of
oral semaglutide was assumed to match that of
once-weekly semaglutide.
Results: Oral semaglutide was associated with
improvements in quality-adjusted life expec-
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tancy of 0.09 quality-adjusted life years (QALYs)
versus empagliflozin, 0.20 QALYs versus sita-
gliptin and 0.07 QALYs versus liraglutide. Direct
costs over a patient’s lifetime were GBP 971 and
GBP 963 higher with oral semaglutide than with
empagliflozin and sitagliptin, respectively, but
GBP 1551 lower versus liraglutide. Oral
semaglutide was associated with a reduced
incidence of diabetes-related complications
versus all comparators. Therefore, oral
semaglutide 14 mg was associated with incre-
mental cost-effectiveness ratios of GBP 11,006
and 4930 per QALY gained versus empagliflozin
25 mg and sitagliptin 100 mg, respectively, and
was more effective and less costly (dominant)
versus liraglutide 1.8 mg.
Conclusion: Oral semaglutide was cost-effec-
tive versus empagliflozin and sitagliptin, and
dominant versus liraglutide, for the treatment
of type 2 diabetes in the UK.
Keywords: Cost effectiveness; Costs and cost
analysis; Diabetes mellitus; Empagliflozin; GLP-
1 receptor agonist; Liraglutide; Oral
semaglutide; Sitagliptin; United Kingdom
Key Summary Points
Why carry out this study?
Type 2 diabetes is associated with a
substantial and increasing clinical and
economic burden in the UK, which
translates into a crucial need for cost-
effective therapies that improve patient
outcomes while minimising costs for the
healthcare payer.
The recent PIONEER clinical trial
programme showed that oral semaglutide,
the first oral medication in its class, was
associated with improved glycaemic
control and reductions in body weight
versus empagliflozin, sitagliptin and
liraglutide, factors that have been
associated with a reduced risk of long-
term diabetes-related complications.
The present analysis used a clinically-
relevant treatment approach to assess the
long-term cost-effectiveness of oral
semaglutide 14 mg versus empagliflozin
25 mg, sitagliptin 100 mg and liraglutide
1.8 mg for the treatment of people with
type 2 diabetes from a healthcare payer
perspective in the UK.
What was learned from the study?
Oral semaglutide 14 mg was projected to
improve both life expectancy and quality-
adjusted life expectancy versus
empagliflozin 25 mg, sitagliptin 100 mg
and liraglutide 1.8 mg.
Direct costs over patient lifetimes were
estimated to be higher with oral
semaglutide versus empagliflozin and
sitagliptin, but lower versus liraglutide,
with costs associated with the treatment
of diabetes-related complications lower
with oral semaglutide in all comparisons.
Oral semaglutide 14 mg was therefore
considered to be a cost-effective treatment
option versus empagliflozin 25 mg,
sitagliptin 100 mg and liraglutide 1.8 mg
for the treatment of type 2 diabetes in the
UK.
INTRODUCTION
Diabetes accounts for a substantial health and
economic burden in the UK, with over 4.7 mil-
lion people living with the disease and over
12.3 million people at an increased risk of
developing the disease in 2018 [1]. Diabetes-re-
lated healthcare expenditure (expressed in
pounds sterling [GBP]) was estimated to be over
GBP 10 billion in 2018, accounting for 10% of
the entire National Health Service (NHS) budget
[1]. An estimated 80% of diabetes-related
expenditure in the UK is associated with the
treatment of long-term complications, with a
more than twofold increase in risk of
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myocardial infarction, heart failure and stroke
in people with type 2 diabetes versus those
without the disease [1]. Interventions that are
cost-effective, offering clinical benefits while
providing value for money, are becoming vital
as healthcare payers’ budgets come under
increasing pressure.
Improvements in glycated haemoglobin
(HbA1c) and blood pressure have long been
associated with reductions in long-term dia-
betes-related complications, as demonstrated in
the landmark United Kingdom Prospective
Diabetes Study (UKPDS), and more recent evi-
dence has suggested that reductions in other
parameters, such as body weight, can provide
further benefits [2–5]. Clinical guidelines pub-
lished by the National Institute for Health and
Care Excellence (NICE) in the UK recommend
an individualised approach for the treatment of
each patient that incorporates personal prefer-
ences and comorbidities [6]. Moreover, the most
recent guidelines released by the European
Association for the Study of Diabetes (EASD)
and the American Diabetes Association (ADA)
recommend a more holistic approach to dia-
betes treatment, rather than a sole focus on
glycaemic control [7]. In particular, updated
recommendations for people with type 2 dia-
betes with established cardiovascular disease or
for those who are overweight or obese or have a
high risk of hypoglycaemia now consider the
effects of therapies on cardiovascular disease,
body weight and hypoglycaemia risk alongside
reductions in HbA1c [7].
Glucagon-like peptide-1 (GLP-1) receptor
agonists represent a highly efficacious class of
interventions for the treatment of type 2 dia-
betes, with the injectable GLP-1 analogue once-
weekly semaglutide shown to be both effica-
cious and cost-effective versus a variety of
therapies [8–11]. However, until recently, GLP-1
receptor agonists have only been available in
injectable formulations, which may have been a
barrier to patient use compared with other
modern treatment options such as sodium-glu-
cose cotransporter-2 (SGLT2) inhibitors and
dipeptidyl peptidase-4 (DPP-4) inhibitors,
which are administered orally. Indeed, in the
UK, injectable GLP-1 receptor agonists are only
recommended as an intensification step for
patients with inadequate glycaemic control
following a triple therapy combination of met-
formin plus a DPP-4 inhibitor with a sulfony-
lurea, pioglitazone or an SGLT2 inhibitor, for
whom insulin therapy would have significant
occupational implications or weight loss would
benefit other obesity-related comorbidities [6].
Given the efficacy benefits GLP-1 receptor ago-
nists appear to offer, earlier intensification to
such medications could overcome the docu-
mented and substantial therapeutic inertia in
people with type 2 diabetes [8–12].
Oral semaglutide is a novel formulation of
the GLP-1 analogue semaglutide developed for
once-daily oral administration, in which the
absorption enhancer sodium N-(8-[2-hydroxy-
benzoyl]amino) caprylate facilitates absorption
across the gastric mucosa. The efficacy and
safety of oral semaglutide has been assessed in
the PIONEER clinical trial programme, with
once-daily oral semaglutide 14 mg compared
with once-daily SGLT2 inhibitor empagliflozin
25 mg in PIONEER 2, with once-daily DPP-4
inhibitor sitagliptin 100 mg in PIONEER 3 and
with once-daily injectable GLP-1 receptor ago-
nist liraglutide 1.8 mg in PIONEER 4 [13–15].
The aim of the present analysis was to assess
the long-term cost-effectiveness of oral
semaglutide 14 mg versus empagliflozin 25 mg,
sitagliptin 100 mg and liraglutide 1.8 mg in the
UK setting, based on the results of the PIONEER
2, 3 and 4 studies, respectively.
METHODS
Modelling Approach
Long-term projections of clinical and cost out-
comes were performed from a healthcare payer
perspective using the IQVIA CORE Diabetes
Model (version 9.0), a proprietary, validated,
internet-based, interactive computer model
developed to determine the long-term health
outcomes and economic consequences of
implementing interventions in the treatment of
type 1 and type 2 diabetes mellitus (accessible at
http://www.core-diabetes.com) [16, 17]. The
architecture, assumptions, features and capa-
bilities of the model have been previously
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published [16]. Validation studies of the model
have been published both in 2004 and more
recently in 2014 [17, 18].
Model outputs include time to onset and
cumulative incidence of complications, life
expectancy, quality-adjusted life expectancy
(QALE; expressed in quality-adjusted life years
[QALYs]), direct costs and, where required,
incremental cost-effectiveness ratios (ICERs),
which describe the cost per additional unit of
effectiveness gained for the intervention versus
the comparator. In comparisons where an
intervention is associated with cost savings
while providing greater clinical benefits, no
calculation of an ICER is required and the
intervention is considered to be dominant ver-
sus the comparator.
Analyses were performed over patient life-
times (up to 50 years), as recommended in the
guidelines for the cost-effectiveness assessment
of interventions for type 2 diabetes, to ensure all
relevant diabetes-related complications and
their impact on clinical and cost outcomes were
captured [19]. The UKPDS 68 risk equations
were applied to predict model outcomes. Back-
ground mortality was captured based on UK-
specific life tables published by the World
Health Organisation (Electronic Supplementary
Material [ESM] Table S1) [20]. Health-state util-
ities and event disutilities were based on pub-
lished sources (ESM Table S2) [21–27].
This article is based on previously conducted
studies and does not contain any studies with
human participants or animals performed by
any of the authors.
Clinical Data
Baseline cohort characteristics and treatment
effects were sourced from the PIONEER 2, 3 and
4 trials for comparisons of oral semaglutide
14 mg with empagliflozin 25 mg, sitagliptin
100 mg and liraglutide 1.8 mg, respectively
(ESM Table S3; Table 1). PIONEER 2 enrolled
people with type 2 diabetes with HbA1c values
between 7.0 and 10.5% (53–91 mmol/mol) who
were receiving metformin; PIONEER 3 enrolled
people with type 2 diabetes with HbA1c values
between 7.0 and 10.5% who were receiving
metformin with or without a sulfonylurea; and
PIONEER 4 enrolled people with type 2 diabetes
with HbA1c values between 7.0 and 9.5% (53–-
80 mmol/mol) who were receiving metformin
with or without an SGLT2 inhibitor. The PIO-
NEER trial programme used two estimands,
namely the treatment policy estimand and the
trial product estimand, to address two different
efficacy questions. The treatment policy esti-
mand reflected the intention-to-treat principle
by including all study participants randomly
assigned to each treatment, using data regard-
less of discontinuation of study medications
and/or use of additional anti-diabetic medica-
tions during the trial [28, 29]. In contrast, the
trial product estimand assessed treatment
effects under the assumption that patients
received the study drug for the duration of the
trial and did not receive any additional anti-
diabetic medications, aiming to reflect the
effects of the study medications without the
confounding effects of rescue medication or any
other changes in glucose-lowering medication
[28]. To match the annual cycle length of the
model, and to avoid the confounding impact of
additional anti-diabetic medications on clinical
and cost outcomes, the analyses were performed
using the 52-week data evaluated by the trial
product estimand. The impact of using data
evaluated by the treatment policy estimand was
explored in a sensitivity analysis.
Treatment Switching and Long-Term
Parameter Progression
Following application of the treatment effects
in the first year of the analysis, HbA1c was
modelled to follow the UKPDS progression
equation, and patients were assumed to receive
oral semaglutide or comparator treatment until
HbA1c exceeded 7.5% (58 mmol/mol), which is
the threshold for treatment intensification
defined in the NICE guidelines [6]. At this stage,
treatment with oral semaglutide or the com-
parator was discontinued, and patients were
assumed to intensify treatment to basal insulin,
with a reduction in HbA1c based on an insulin-
naı¨ve population derived from the ‘‘Core’’ mul-
tivariate equations estimated by Willis et al.
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[30]. HbA1c was subsequently modelled to fol-
low the UKPDS progression equation for the
remainder of patient lifetimes. This approach
was chosen to mirror the HbA1c progression
used by NICE for evaluating SGLT2 inhibitors as
monotherapy in the UK and to reflect common
clinical practice in which, due to the progressive
nature of type 2 diabetes, glycaemic control
Table 1 Treatment effects and adverse event rates sourced from the PIONEER 2, 3 and 4 trials that were applied in the
analyses
Parameter PIONEER 2 PIONEER 3 PIONEER 4
Oral
semaglutide
14 mg
Empagliflozin
25 mg
Oral
semaglutide
14 mg
Sitagliptin
100 mg
Oral
semaglutide
14 mg
Liraglutide
1.8 mg
Physiological parameters applied in the first year of the analysis, mean (SE)
HbA1c (%) - 1.30
(0.05)*
- 0.79 (0.05) - 1.25
(0.05)*
- 0.52
(0.05)
- 1.19
(0.06)*
- 0.92
(0.06)
Systolic blood pressure
(mmHg)
- 4.85
(0.65)
- 4.34 (0.63) - 3.13
(0.63)*
- 0.82
(0.61)
- 3.36
(0.75)
- 2.86
(0.74)
Diastolic blood pressure
(mmHg)
- 2.27
(0.45)
- 2.67 (0.44) - 1.07
(0.39)
- 0.92
(0.38)
- 1.10
(0.45)
- 1.05
(0.44)
Total cholesterol (mg/dL)a - 5.08
(1.62)*
4.74 (1.57) - 3.66
(1.50)*
1.02 (0.57) - 5.47
(2.07)
- 5.36
(2.05)
HDL cholesterol (mg/dL)a 0.73 (0.35)* 3.11 (0.34) 0.54 (0.34) 0.20 (0.35) 1.17 (0.41) 0.23 (0.41)
BMI (kg/m2) - 1.73
(0.10)*
- 1.37 (0.09) - 1.36
(0.07)*
- 0.32
(0.07)
- 1.82
(0.11)*
- 1.11
(0.11)
Hypoglycaemic event rates applied while patients received treatment
Non-severe hypoglycaemic
event rate (events per 100
patient-years)b
2.25 1.90 12.12 11.99 0.71 3.16
Severe hypoglycaemic event
rate (events per 100
patient-years)b
0.25 0.24 0.24 0.90 0.00 0.00
Proportion of non-severe
hypoglycaemic events that
are nocturnalb
0.11 0.13 0.14 0.13 0.00 0.11
Proportion of severe
hypoglycaemic events that
are nocturnalb
0.00 0.00 0.00 0.00 0.00 0.00
*Statistically significant difference at the 95% confidence level
Hypoglycaemic events were assessed as safety endpoints at 57 weeks in PIONEER 2 and 4 and 52 weeks in PIONEER 3
[13–15]. All data, unless otherwise indicated, were evaluated by the trial product estimand at 52 weeks [13–15]
BMI Body mass index, HbA1c glycated haemoglobin, HDL high-density lipoprotein, SE standard error
a Estimated with an arithmetic mean
b Data on file (not previously published)
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cannot be maintained indefinitely by the addi-
tion of one medication [7, 31]. Variations in the
thresholds for treatment switching and further
treatment intensification to basal–bolus insulin
were explored in sensitivity analyses.
Body mass index (BMI) benefits were
assumed to persist while patients received either
oral semaglutide or comparator treatment,
before reverting to baseline following intensifi-
cation to basal insulin therapy. Therefore, no
difference in BMI was seen between the patient
arms following treatment intensification with
basal insulin.
Changes in blood pressure and serum lipids
were assumed to follow the natural progression
algorithms built into the IQVIA CORE Diabetes
Model in all arms, based on the UKPDS or
Framingham data (as described by Palmer et al.
[16]), following application of the treatment
effects in the first year of the analysis. Hypo-
glycaemia rates following treatment intensifi-
cation were based on published data, with non-
severe and severe hypoglycaemic events pro-
jected to increase to 4.08 and 0.10 events per
patient per year, respectively [32].
Cost Data
Costs were accounted from a UK healthcare
payer perspective. Captured direct costs inclu-
ded pharmacy costs, costs associated with dia-
betes-related complications and patient
management costs (ESM Tables S4, S5). The
annual acquisition cost of oral semaglutide was
assumed to be the same as that of once-weekly
semaglutide, based on the similar level of pric-
ing seen between the GLP-1 analogues in the US
market. Costs of other included medications
and consumables were based on published list
prices (sourced in July 2019), while costs of
diabetes-related complications were identified
through a 2017 literature review and updated or
inflated where necessary to the most recent
costs available (2018 GBP) using published NHS
diagnosis-related groups and the healthcare
inflation index published by the Personal Social
Services Research Unit [33–42]. No self-moni-
toring of blood glucose (SMBG) testing costs
were associated with oral semaglutide,
empagliflozin, sitagliptin or liraglutide, as all
these interventions are associated with low rates
of hypoglycaemia and, consequently, little to
no SMBG testing would be required. No needles
were required for the administration of oral
semaglutide, empagliflozin or sitagliptin as
these medications are administered orally, but
one needle per day was required for the
administration of liraglutide. Following treat-
ment intensification to basal insulin (assumed
to be insulin Abasaglar, the most widely used
biosimilar of insulin glargine in the UK),
patients were assumed to require one SMBG test
per day and to use one needle per day for the
administration of basal insulin.
Sensitivity Analyses
The extrapolation of clinical results by mod-
elling the long-term consequences is associated
with uncertainty. Sensitivity analyses were
therefore performed on key parameters in the
modelling analysis to assess the robustness of
the base case findings. Sensitivity analyses
conducted for all comparisons included: apply-
ing only statistically significant differences
between the treatment arms; shortening the
time horizon of the analyses to 35, 20 and
10 years (for which it should be noted that some
patients were still alive at the end of the mod-
elling period and, therefore, not all costs and
consequences were captured); applying dis-
count rates of 0 and 6% in separate analyses;
applying the upper and lower limits of the 95%
confidence intervals for the estimated treat-
ment differences in HbA1c and BMI in separate
analyses; maintaining BMI treatment effects for
patient lifetimes; altering the HbA1c threshold
for treatment intensification to 7.0%
(53 mmol/mol) and 8.0% (64 mmol/mol);
applying a second treatment intensification
step to basal–bolus insulin at an HbA1c thresh-
old of 7.5% (58 mmol/mol); exploring the effect
of applying alternative basal insulin costs (in-
sulin neutral protamine Hagedorn [NPH], Sem-
glee [Mylan, biosimilar of insulin glargine] and
Lantus [insulin glargine]) following treatment
intensification; increasing and decreasing the
annual acquisition cost of oral semaglutide by
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5% in separate analyses; application of the
liraglutide 1.2 mg price in the liraglutide arm of
PIONEER 4; increasing and decreasing the costs
of complications by 10% in separate analyses;
applying an alternative cost of stroke in the year
of the event and in subsequent years, based on a
publication by Patel et al. [43]; applying the
UKPDS 82 risk equations to predict model out-
comes; application of alternative disutilities for
increases in BMI (based on a publication by Lee
et al. [26]) and hypoglycaemic events (based on
publications by Currie et al. [44] and Lauridsen
et al. [45]); application of the 26-week clinical
data; and application of data evaluated by the
treatment policy estimand from the PIONEER 2,
3 and 4 clinical trials [13–15].
Probabilistic sensitivity analyses (PSA) were
also performed using a second-order Monte
Carlo approach. Cohort characteristics, treat-
ment effects and complication costs and utili-
ties were sampled from distributions, with
cohorts of 1000 patients run through the model
1000 times.
RESULTS
Base Case Analysis
Long-term projections of clinical outcomes
indicated that oral semaglutide 14 mg was
associated with improvements in discounted
Table 2 Long-term cost-effectiveness outcomes
Health outcomes PIONEER 2
Oral semaglutide 14 mg Empagliflozin 25 mg Difference
Discounted life expectancy (years) 13.19 13.13 ? 0.06
Discounted QALE (QALYs) 8.58 8.49 ?0.09
Discounted direct costs (GBP) 25,856 24,885 ? 971
ICER GBP 11,006 per QALY gained
Health outcomes PIONEER 3
Oral semaglutide 14 mg Sitagliptin 100 mg Difference
Discounted life expectancy (years) 12.74 12.57 ? 0.17
Discounted QALE (QALYs) 8.20 8.00 ? 0.20
Discounted direct costs (GBP) 27,226 26,263 ? 963
ICER GBP 4930 per QALY gained
Health outcomes PIONEER 4
Oral semaglutide 14 mg Liraglutide 1.8 mg Difference
Discounted life expectancy (years) 13.28 13.21 ? 0.07
Discounted QALE (QALYs) 8.53 8.46 ? 0.07
Discounted direct costs (GBP) 27,868 29,418 - 1551
ICER Oral semaglutide dominant
Values are given as mean values
GBP Pounds sterling, ICER incremental cost-effectiveness ratio, QALE quality-adjusted life expectancy, QALY quality-
adjusted life year
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life expectancy of 0.06, 0.17 and 0.07 years and
improvements in discounted QALE of 0.09, 0.20
and 0.07 QALYs versus empagliflozin 25 mg,
sitagliptin 100 mg and liraglutide 1.8 mg,
respectively (Table 2). Clinical benefits arose
from a reduced incidence of diabetes-related
complications with oral semaglutide in all
comparisons. The mean times to any diabetes-
related complication in the analyses were
lengthened with oral semaglutide 14 mg treat-
ment by 0.2 years versus empagliflozin 25 mg
and sitagliptin 100 mg and by 0.1 years versus
liraglutide 1.8 mg.
Oral semaglutide was associated with direct
cost increases of GBP 971 and GBP 963 versus
empagliflozin 25 mg and sitagliptin 100 mg,
respectively, over patient lifetimes, driven by
the assumed higher acquisition cost of oral
semaglutide and the differential times to treat-
ment intensification, with patients receiving
oral semaglutide for 1 additional year in the
comparison with empagliflozin and for 2 addi-
tional years in the comparison with sitagliptin
(Fig. 1). However, higher treatment costs were
partially offset by cost savings due to avoidance
of diabetes-related complications, most notably
avoided cardiovascular complications (mean
cost savings of GBP 99 per patient compared
with empagliflozin 25 mg and of GBP 146 per
patient compared with sitagliptin 100 mg). In
the analyses based on PIONEER 4, oral
semaglutide 14 mg was associated with esti-
mated cost savings of GBP 1551 versus liraglu-
tide 1.8 mg over patient lifetimes, driven by the
lower acquisition cost of oral semaglutide. Fur-
ther cost savings were achieved through
reduced needle use (with none required for oral
semaglutide versus one per day for liraglutide)
and avoidance of diabetes-related complications
with oral semaglutide, most notably avoided
cardiovascular complications (mean cost sav-
ings of GBP 101 per patient).
In the analyses based on PIONEER 2 and 3,
oral semaglutide 14 mg was associated with
improved clinical outcomes and increased costs
from a healthcare payer perspective, yielding
ICERs of GBP 11,006 and GBP 4930 per QALY
gained versus empagliflozin 25 mg and sita-
gliptin 100 mg, respectively. Based on the
commonly-quoted willingness-to-pay threshold
of GBP 20,000 per QALY gained in the UK, oral
semaglutide 14 mg represents a cost-effective
treatment option versus both empagliflozin
25 mg and sitagliptin 100 mg. In the analyses
based on PIONEER 4, oral semaglutide 14 mg
was associated with improved clinical outcomes
and reduced costs versus liraglutide 1.8 mg, and
it was therefore considered to be dominant.
Deterministic Sensitivity Analyses
Sensitivity analyses showed that the results of
the cost-effectiveness analyses comparing oral
semaglutide 14 mg with empagliflozin 25 mg,
sitagliptin 100 mg and liraglutide 1.8 mg were
robust to changes in the input parameters and
assumptions used (Table 3).
Oral Semaglutide Versus Empagliflozin
(PIONEER 2)
For the analyses based on PIONEER 2, the big-
gest change in the ICER from the base case
analysis was seen when applying a 10-year time
horizon. At this time horizon, clinical benefits
Fig. 1 Direct cost outcomes over patient lifetimes. GBP
Pounds sterling
Diabetes Ther
T
ab
le
3
Se
ns
it
iv
it
y
an
al
ys
es
re
su
lts
A
na
ly
si
s
O
ra
ls
em
ag
lu
ti
de
14
m
g
vs
.e
m
pa
gl
ifl
oz
in
25
m
g
(P
IO
N
E
E
R
2)
O
ra
l
se
m
ag
lu
ti
de
14
m
g
vs
.
si
ta
gl
ip
ti
n
10
0
m
g
(P
IO
N
E
E
R
3)
O
ra
l
se
m
ag
lu
ti
de
14
m
g
vs
.
lir
ag
lu
ti
de
1.
8
m
g
(P
IO
N
E
E
R
4)
D D
is
co
un
te
d
Q
A
L
E
(Q
A
L
Y
s)
D D
is
co
un
te
d
di
re
ct
co
st
s
(G
B
P
)
IC
E
R
(G
B
P
pe
r
Q
A
L
Y
ga
in
ed
)
D D
is
co
un
te
d
Q
A
L
E
(Q
A
L
Y
s)
D D
is
co
un
te
d
di
re
ct
co
st
s
(G
B
P
)
IC
E
R
(G
B
P
pe
r
Q
A
L
Y
ga
in
ed
)
D D
is
co
un
te
d
Q
A
L
E
(Q
A
L
Y
s)
D D
is
co
un
te
d
di
re
ct
co
st
s
(G
B
P
)
IC
E
R
(G
B
P
pe
r
Q
A
L
Y
ga
in
ed
)a
B
as
e
ca
se
?
0.
09
?
97
1
11
,0
06
?
0.
20
?
96
3
49
30
?
0.
07
-
15
51
O
ra
l
se
m
ag
lu
ti
de
do
m
in
an
t
St
at
is
ti
ca
lly
si
gn
ifi
ca
nt
di
ff
er
en
ce
s
on
ly
?
0.
08
?
97
3
11
,6
05
?
0.
19
?
96
0
50
48
?
0.
06
-
15
72
O
ra
l
se
m
ag
lu
ti
de
do
m
in
an
t
35
-y
ea
r
ti
m
e
ho
ri
zo
n
?
0.
09
?
10
74
11
,5
72
?
0.
19
?
85
5
45
32
?
0.
07
-
14
73
O
ra
l
se
m
ag
lu
ti
de
do
m
in
an
t
20
-y
ea
r
ti
m
e
ho
ri
zo
n
?
0.
08
?
99
9
12
,9
24
?
0.
15
?
81
1
54
38
?
0.
03
-
14
92
O
ra
l
se
m
ag
lu
ti
de
do
m
in
an
t
10
-y
ea
r
ti
m
e
ho
ri
zo
n
?
0.
05
?
11
76
21
,8
21
?
0.
09
?
10
60
11
,2
32
?
0.
03
-
14
92
O
ra
l
se
m
ag
lu
ti
de
do
m
in
an
t
0%
D
is
co
un
t
ra
te
s
?
0.
14
?
90
6
66
93
?
0.
32
?
10
49
33
33
?
0.
12
-
16
46
O
ra
l
se
m
ag
lu
ti
de
do
m
in
an
t
6%
D
is
co
un
t
ra
te
s
?
0.
07
?
98
8
14
,1
82
?
0.
15
?
95
4
63
15
?
0.
05
-
14
67
O
ra
l
se
m
ag
lu
ti
de
do
m
in
an
t
U
pp
er
95
%
C
I
of
H
bA
1c
E
T
D
?
0.
11
?
82
8
76
15
?
0.
14
?
66
7
48
40
?
0.
06
-
14
52
O
ra
l
se
m
ag
lu
ti
de
do
m
in
an
t
Diabetes Ther
T
a
b
le
3
co
n
ti
n
u
ed
A
na
ly
si
s
O
ra
ls
em
ag
lu
ti
de
14
m
g
vs
.e
m
pa
gl
ifl
oz
in
25
m
g
(P
IO
N
E
E
R
2)
O
ra
l
se
m
ag
lu
ti
de
14
m
g
vs
.
si
ta
gl
ip
ti
n
10
0
m
g
(P
IO
N
E
E
R
3)
O
ra
l
se
m
ag
lu
ti
de
14
m
g
vs
.
lir
ag
lu
ti
de
1.
8
m
g
(P
IO
N
E
E
R
4)
D D
is
co
un
te
d
Q
A
L
E
(Q
A
L
Y
s)
D D
is
co
un
te
d
di
re
ct
co
st
s
(G
B
P
)
IC
E
R
(G
B
P
pe
r
Q
A
L
Y
ga
in
ed
)
D D
is
co
un
te
d
Q
A
L
E
(Q
A
L
Y
s)
D D
is
co
un
te
d
di
re
ct
co
st
s
(G
B
P
)
IC
E
R
(G
B
P
pe
r
Q
A
L
Y
ga
in
ed
)
D D
is
co
un
te
d
Q
A
L
E
(Q
A
L
Y
s)
D D
is
co
un
te
d
di
re
ct
co
st
s
(G
B
P
)
IC
E
R
(G
B
P
pe
r
Q
A
L
Y
ga
in
ed
)a
L
ow
er
95
%
C
I
of
H
bA
1c
E
T
D
?
0.
08
?
10
98
13
,2
11
?
0.
20
?
88
0
43
07
?
0.
13
-
12
27
O
ra
l
se
m
ag
lu
ti
de
do
m
in
an
t
U
pp
er
95
%
C
I
of
B
M
I
E
T
D
?
0.
10
?
97
6
93
71
?
0.
18
?
96
1
52
78
?
0.
06
-
15
64
O
ra
l
se
m
ag
lu
ti
de
do
m
in
an
t
L
ow
er
95
%
C
I
of
B
M
I
E
T
D
?
0.
07
?
94
2
13
,7
52
?
0.
20
?
98
5
48
46
?
0.
08
-
15
29
O
ra
l
se
m
ag
lu
ti
de
do
m
in
an
t
B
M
I
di
ff
er
en
ce
m
ai
nt
ai
ne
d
fo
r
pa
ti
en
t
lif
et
im
es
?
0.
12
?
97
8
82
57
?
0.
25
?
97
1
38
17
?
0.
07
-
15
62
O
ra
l
se
m
ag
lu
ti
de
do
m
in
an
t
T
re
at
m
en
t
sw
it
ch
in
g
at
7.
0%
H
bA
1c
?
0.
11
?
55
7
52
32
?
0.
11
?
16
8
15
14
?
0.
09
-
30
5
O
ra
l
se
m
ag
lu
ti
de
do
m
in
an
t
T
re
at
m
en
t
sw
it
ch
in
g
at
8.
0%
H
bA
1c
?
0.
10
?
17
26
17
,5
45
?
0.
19
?
13
33
69
77
?
0.
07
-
23
87
O
ra
l
se
m
ag
lu
ti
de
do
m
in
an
t
Se
co
nd
tr
ea
tm
en
t
in
te
ns
ifi
ca
ti
on
at
7.
5%
H
bA
1c
to
ba
sa
l–
bo
lu
s
?
0.
15
?
65
4
43
16
?
0.
27
?
21
0
77
9
?
0.
07
-
14
20
O
ra
l
se
m
ag
lu
ti
de
do
m
in
an
t
Diabetes Ther
T
a
b
le
3
co
n
ti
n
u
ed
A
na
ly
si
s
O
ra
ls
em
ag
lu
ti
de
14
m
g
vs
.e
m
pa
gl
ifl
oz
in
25
m
g
(P
IO
N
E
E
R
2)
O
ra
l
se
m
ag
lu
ti
de
14
m
g
vs
.
si
ta
gl
ip
ti
n
10
0
m
g
(P
IO
N
E
E
R
3)
O
ra
l
se
m
ag
lu
ti
de
14
m
g
vs
.
lir
ag
lu
ti
de
1.
8
m
g
(P
IO
N
E
E
R
4)
D D
is
co
un
te
d
Q
A
L
E
(Q
A
L
Y
s)
D D
is
co
un
te
d
di
re
ct
co
st
s
(G
B
P
)
IC
E
R
(G
B
P
pe
r
Q
A
L
Y
ga
in
ed
)
D D
is
co
un
te
d
Q
A
L
E
(Q
A
L
Y
s)
D D
is
co
un
te
d
di
re
ct
co
st
s
(G
B
P
)
IC
E
R
(G
B
P
pe
r
Q
A
L
Y
ga
in
ed
)
D D
is
co
un
te
d
Q
A
L
E
(Q
A
L
Y
s)
D D
is
co
un
te
d
di
re
ct
co
st
s
(G
B
P
)
IC
E
R
(G
B
P
pe
r
Q
A
L
Y
ga
in
ed
)a
N
PH
ba
sa
l
in
su
lin
co
st
ap
pl
ie
d
?
0.
09
?
11
11
12
,6
00
?
0.
20
?
12
37
63
34
?
0.
07
-
15
62
O
ra
l
se
m
ag
lu
ti
de
do
m
in
an
t
L
an
tu
s
co
st
ap
pl
ie
d
?
0.
09
?
10
82
12
,2
67
?
0.
20
?
10
54
53
97
?
0.
07
-
14
18
O
ra
l
se
m
ag
lu
ti
de
do
m
in
an
t
Se
m
gl
ee
co
st
ap
pl
ie
d
?
0.
09
?
10
13
11
,4
80
?
0.
20
?
10
44
53
48
?
0.
07
-
15
54
O
ra
l
se
m
ag
lu
ti
de
do
m
in
an
t
O
ra
l
se
m
ag
lu
ti
de
pr
ic
e
?
5%
?
0.
09
?
11
02
12
,4
90
?
0.
20
?
10
92
55
94
?
0.
07
-
14
20
O
ra
l
se
m
ag
lu
ti
de
do
m
in
an
t
O
ra
l
se
m
ag
lu
ti
de
pr
ic
e
-
5%
?
0.
09
?
84
0
95
22
?
0.
20
?
83
3
42
66
?
0.
07
-
16
81
O
ra
l
se
m
ag
lu
ti
de
do
m
in
an
t
L
ir
ag
lu
ti
de
1.
2
m
g
pr
ic
e
ap
pl
ie
d
–
–
–
–
–
–
?
0.
07
-
24
6
O
ra
l
se
m
ag
lu
ti
de
do
m
in
an
t
C
os
t
of
co
m
pl
ic
at
io
ns
?
10
%
?
0.
09
?
93
3
10
,5
83
?
0.
20
?
91
5
46
87
?
0.
07
-
15
70
O
ra
l
se
m
ag
lu
ti
de
do
m
in
an
t
C
os
t
of
co
m
pl
ic
at
io
ns
-
10
%
?
0.
09
?
10
11
11
,4
67
?
0.
20
?
10
17
52
06
?
0.
07
-
15
31
O
ra
l
se
m
ag
lu
ti
de
do
m
in
an
t
Diabetes Ther
T
a
b
le
3
co
n
ti
n
u
ed
A
na
ly
si
s
O
ra
ls
em
ag
lu
ti
de
14
m
g
vs
.e
m
pa
gl
ifl
oz
in
25
m
g
(P
IO
N
E
E
R
2)
O
ra
l
se
m
ag
lu
ti
de
14
m
g
vs
.
si
ta
gl
ip
ti
n
10
0
m
g
(P
IO
N
E
E
R
3)
O
ra
l
se
m
ag
lu
ti
de
14
m
g
vs
.
lir
ag
lu
ti
de
1.
8
m
g
(P
IO
N
E
E
R
4)
D D
is
co
un
te
d
Q
A
L
E
(Q
A
L
Y
s)
D D
is
co
un
te
d
di
re
ct
co
st
s
(G
B
P
)
IC
E
R
(G
B
P
pe
r
Q
A
L
Y
ga
in
ed
)
D D
is
co
un
te
d
Q
A
L
E
(Q
A
L
Y
s)
D D
is
co
un
te
d
di
re
ct
co
st
s
(G
B
P
)
IC
E
R
(G
B
P
pe
r
Q
A
L
Y
ga
in
ed
)
D D
is
co
un
te
d
Q
A
L
E
(Q
A
L
Y
s)
D D
is
co
un
te
d
di
re
ct
co
st
s
(G
B
P
)
IC
E
R
(G
B
P
pe
r
Q
A
L
Y
ga
in
ed
)a
A
lte
rn
at
iv
e
co
st
s
of
st
ro
ke
ap
pl
ie
d
?
0.
09
?
96
8
10
,9
73
?
0.
20
?
94
6
48
46
?
0.
07
-
15
51
O
ra
l
se
m
ag
lu
ti
de
do
m
in
an
t
U
K
PD
S
82
ri
sk
eq
ua
ti
on
s
ap
pl
ie
d
?
0.
07
?
10
26
14
,0
41
?
0.
14
?
80
6
56
71
?
0.
03
-
15
20
O
ra
l
se
m
ag
lu
ti
de
do
m
in
an
t
L
ee
et
al
.[
26
]
B
M
I
di
su
ti
lit
y
ap
pl
ie
d
?
0.
10
?
97
1
10
,2
19
?
0.
20
?
96
3
47
29
?
0.
07
-
15
51
O
ra
l
se
m
ag
lu
ti
de
do
m
in
an
t
D
im
in
is
hi
ng
hy
po
gl
yc
ae
m
ia
di
su
ti
lit
y
m
od
el
?
0.
09
?
97
1
10
,9
20
?
0.
20
?
96
3
49
22
?
0.
07
-
15
51
O
ra
l
se
m
ag
lu
ti
de
do
m
in
an
t
C
ur
ri
e
et
al
.[
44
]
hy
po
gl
yc
ae
m
ia
di
su
ti
lit
ie
s
?
0.
08
?
97
1
12
,1
95
?
0.
18
?
96
3
54
09
?
0.
07
-
15
51
O
ra
l
se
m
ag
lu
ti
de
do
m
in
an
t
26
-w
ee
k
tr
ea
tm
en
t
ef
fe
ct
s
ap
pl
ie
d
?
0.
07
?
10
79
15
,4
13
?
0.
15
?
87
2
58
74
?
0.
08
-
11
08
O
ra
l
se
m
ag
lu
ti
de
do
m
in
an
t
T
re
at
m
en
t
po
lic
y
es
ti
m
an
d
?
0.
06
?
72
2
12
,2
74
?
0.
12
?
58
4
47
04
?
0.
05
-
13
56
O
ra
l
se
m
ag
lu
ti
de
do
m
in
an
t
C
I
C
on
fid
en
ce
in
te
rv
al
,D
di
ff
er
en
ce
in
,E
T
D
es
ti
m
at
ed
tr
ea
tm
en
t
di
ff
er
en
ce
,N
PH
ne
ut
ra
lp
ro
ta
m
in
e
H
ag
ed
or
n,
U
K
PD
S
U
ni
te
d
K
in
gd
om
Pr
os
pe
ct
iv
e
D
ia
be
te
s
St
ud
y
a
D
om
in
an
t
in
di
ca
te
s
th
at
th
e
in
te
rv
en
ti
on
is
as
so
ci
at
ed
w
it
h
im
pr
ov
ed
cl
in
ic
al
ou
tc
om
es
an
d
co
st
sa
vi
ng
s
Diabetes Ther
with oral semaglutide 14 mg were reduced and
incremental costs were increased, yielding an
ICER of GBP 21,821 per QALY gained versus
empagliflozin 25 mg. However, this was due to
the shorter time horizon of the analysis not
capturing all of the long-term diabetes-related
complications patients may experience, and
their subsequent impact on clinical and cost
outcomes. The largest reduction in the ICER was
observed when applying a second treatment
intensification step to basal–bolus insulin at an
HbA1c switching threshold of 7.5%
(58 mmol/mol), which resulted in increased
clinical benefits and reduced incremental costs
with oral semaglutide and an ICER of GBP 4316
per QALY gained.
Lowering the HbA1c treatment switching
threshold to 7.0% (53 mmol/mol) also greatly
influenced cost-effectiveness outcomes, reduc-
ing the incremental costs associated with oral
semaglutide while increasing the incremental
clinical benefits. This resulted in an ICER of
GBP 5232 per QALY gained versus empagli-
flozin. Conversely, application of an 8.0%
HbA1c (64 mmol/mol) treatment switching
threshold yielded increased incremental costs
and an ICER of GBP 17,545 per QALY gained for
oral semaglutide versus empagliflozin.
All other sensitivity analyses yielded similar
ICERs to the base case analysis.
Oral Semaglutide Versus Sitagliptin (PIONEER
3)
For the analyses based on PIONEER 3, the largest
change in the ICER was also observed when
applying a 10-year time horizon. Clinical benefits
with oral semaglutide 14 mgwere greatly reduced
at this timehorizon,while incremental costswere
increased, resulting in an ICER of GBP 11,232 per
QALY gained versus sitagliptin 100 mg. Perform-
ing a second treatment intensification to
basal–bolus insulin at a 7.5% (58 mmol/mol)
HbA1c switching threshold led to greatly
increased clinical benefits and reduced incre-
mental costs, and an ICER of GBP 779 per QALY
gained.
Using a lower 7.0% (53 mmol/mol) HbA1c
threshold for treatment switching lowered the
clinical benefits associated with oral semaglu-
tide but also reduced incremental costs, yielding
an ICER of GBP 1514 per QALY gained. Apply-
ing a higher 8.0% (64 mmol/mol) HbA1c
switching threshold also led to lowered clinical
benefits but with increased incremental costs,
and oral semaglutide was associated with an
ICER of GBP 6977 per QALY gained versus sita-
gliptin. Maintaining the treatment effects of
BMI for patient lifetimes resulted in increased
clinical benefits with oral semaglutide, and
incremental costs similar to the base case anal-
ysis, yielding an ICER of GBP 3817 per QALY
gained versus sitagliptin.
The ICERs in all other sensitivity analyses
remained similar to the base case analysis.
Oral Semaglutide Versus Liraglutide
(PIONEER 4)
For the analyses based on PIONEER 4, the base
case conclusion that oral semaglutide was
dominant versus liraglutide did not change.
Application of shorter time horizons lowered
the clinical benefits observed with oral
semaglutide, while application of a 7.0%
(53 mmol/mol) HbA1c threshold for treatment
switching and the liraglutide 1.2 mg price in the
liraglutide 1.8 mg arm yielded lower cost sav-
ings with oral semaglutide. However, clinical
and cost benefits remained consistently in
favour of oral semaglutide 14 mg throughout all
analyses, and it remained dominant versus
liraglutide 1.8 mg.
Probabilistic Sensitivity Analysis
The PSA with sampling across cohort charac-
teristics, treatment effects, complication costs
and utilities showed similar mean results to the
base case analyses but increased measures of
variance around the mean outcomes (Fig. 2).
The mean incremental improvements in QALE
with oral semaglutide 14 mg were 0.09, 0.18
and 0.07 QALYs versus empagliflozin 25 mg,
sitagliptin 100 mg and liraglutide 1.8 mg,
respectively. Mean costs were estimated to be
GBP 1021 and GBP 817 higher with oral
semaglutide than with empagliflozin and sita-
gliptin, respectively, but GBP 1177 lower versus
liraglutide. This resulted in ICERs of GBP 11,580
and GBP 4620 per QALY gained for oral
Diabetes Ther
semaglutide 14 mg versus empagliflozin 25 mg
and sitagliptin 100 mg, respectively, while oral
semaglutide 14 mg was considered dominant
versus liraglutide 1.8 mg. At a willingness-to-
pay threshold of GBP 20,000 per QALY gained,
the probabilities of oral semaglutide 14 mg
being cost-effective versus empagliflozin 25 mg,
sitagliptin 100 mg and liraglutide 1.8 mg were
59.9, 77.6 and 79.5%, respectively, while at a
willingness-to-pay threshold of GBP 30,000 per
QALY gained, these probabilities were estimated
to be 64.3, 80.2 and 74.7%, respectively (Fig. 3).
DISCUSSION
Based on long-term projections of clinical and
cost outcomes, oral semaglutide 14 mg offers a
cost-effective treatment option versus other
modern treatments for type 2 diabetes, includ-
ing empagliflozin 25 mg, sitagliptin 100 mg and
liraglutide 1.8 mg. The observed clinical bene-
fits were the result of a reduced incidence and
delayed time to onset of long-term diabetes-re-
lated complications with oral semaglutide.
Diabetes-related complications were fewer with
oral semaglutide 14 mg, which yielded cost
savings that partially offset its higher treatment
costs versus empagliflozin and sitagliptin. Oral
semaglutide was associated with lower treat-
ment costs versus liraglutide, with further cost
savings achieved through a reduced incidence
of diabetes-related complications. Oral
semaglutide 14 mg was therefore associated
with ICERs of GBP 11,006 and GBP 4930 per
QALY gained versus empagliflozin 25 mg and
Fig. 2 Cost-effectiveness scatterplot based on the probabilistic sensitivity analyses. QALY quality-adjusted life year
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sitagliptin 100 mg, respectively, and was con-
sidered to be cost effective based on a willing-
ness-to-pay threshold of GBP 20,000 per QALY
gained. With improved clinical outcomes and
reduced costs, oral semaglutide 14 mg was
considered to be dominant versus liraglutide
1.8 mg.
Oral semaglutide is the first GLP-1 receptor
agonist available for oral administration. Offer-
ing patients the benefits of a GLP-1 receptor
agonist in a once-daily tablet could overcome
some of the obstacles that lead to therapeutic
inertia, as evidence suggests that patient con-
cerns over potential side effects of therapies,
including hypoglycaemia and weight gain, as
well as fear of injections, often lead to delayed
intensification of treatment, despite poor gly-
caemic control [12, 46–48]. The PIONEER clin-
ical trial programme enrolled patients receiving
differing background therapies, with PIONEER 2
enrolling patients with inadequate glycaemic
control on metformin, PIONEER 3 enrolling
patients with inadequate glycaemic control on
metformin with or without a sulfonylurea, and
PIONEER 4 enrolling patients with inadequate
glycaemic control on metformin with or with-
out an SGLT2 inhibitor [13–15]. As shown in
the present study, oral semaglutide represents a
cost-effective treatment option in all of these
patient populations. Moreover, while the lower
1.2 mg dose of liraglutide is commonly recom-
mended in the UK for the majority of patients,
the present study has demonstrated that oral
semaglutide remains more effective and less
costly versus the more efficacious 1.8 mg dose of
liraglutide when the lower 1.2 mg price is
applied.
The present analysis used a clinically-rele-
vant approach for HbA1c progression and
treatment intensification, which is in line with
recent publications and cost-effectiveness
assessments of GLP-1 receptor agonists and
SGLT2 inhibitors [10, 31]. This strategy is rep-
resentative of clinical practice in a real-world
Fig. 3 Cost-effectiveness acceptability curves based on the probabilistic sensitivity analyses
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population with type 2 diabetes, with patients
contining treatments while they remain within
their glycaemic target, intensification becoming
necessary as the disease progresses and gly-
caemic control becoming increasingly chal-
lenging over the long term. Indeed, the latest
EASD/ADA guidelines recommend that patients
are evaluated every 3–6 months to ensure
treatments are performing effectively, and
clinical guidelines published by NICE in the UK
recommend treatment intensification at a 7.5%
(58 mmol/mol) HbA1c threshold [6, 7]. The use
of the multivariate equations published by
Willis et al. [30] to estimate changes in HbA1c
on the initiation of basal insulin therapy also
represents a key strength of the present analysis.
These equations are informed by a variety of
sources captured in a literature review, allowing
the analyses to avoid the use of specific treat-
ment effects designed to artificially improve
model outcomes. Therefore, the present study
offers a highly relevant approach to real-world
practice, where glycaemic control cannot be
maintained indefinitely with one medication.
However, a potential limitation of this
approach is the use of the UKPDS equations for
HbA1c progression, as these are based on data
from 20 years ago and as such may no longer be
as applicable in modern clinical practice.
Nonetheless, there are no readily available long-
term type 2 diabetes studies equivalent in
length to the UKPDS to test this.
When evaluating the clinical and cost out-
comes associated with the interventions inclu-
ded in the present analysis, it is important to
consider the impact of differential treatment
switching occurring due to the 7.5%
(58 mmol/mol) HbA1c threshold. In the long-
term projections based on PIONEER 2, patients
received empagliflozin 25 mg for 2 years and
oral semaglutide 14 mg for 3 years, while in the
projections based on PIONEER 3, patients
received sitagliptin 100 mg for 1 year and oral
semaglutide 14 mg for 3 years. This improved
glycaemic control resulted in initial treatment
costs being maintained for 1 additional year in
the analyses based on PIONEER 2 and for 2
additional years in the analyses based on PIO-
NEER 3. However, alternative HbA1c thresholds
were tested, including adding a further
treatment intensification step to basal–bolus
insulin, and these analyses did not change the
conclusion that oral semaglutide is cost-
effective.
A limitation inherent in all long-term health
economic analyses is the reliance on short-term
clinical trial data to project outcomes over
patient lifetimes. However, this is an essential
tenet of all long-term diabetes modelling and
arguably represents the best source of evidence
for decision-making in the absence of long-term
clinical trial data. The use of 52-week data from
the PIONEER trials, matching the annual cycle
length of the model, also represents a strength
of the analysis. Moreover, the variety of sensi-
tivity analyses performed with different treat-
ment switching assumptions and time horizons
did not change the conclusion that oral
semaglutide is cost-effective.
CONCLUSIONS
Oral semaglutide 14 mg was projected to be a
cost-effective treatment option versus empagli-
flozin 25 mg, sitagliptin 100 mg and liraglutide
1.8 mg for the treatment of patients with type 2
diabetes in the UK.
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